Book Review: Calling All Canines…And Their Owners by Sheri Venza

Dog behaviorist and trainer Sheri Venza puts her over 20 years of experience into a practical, usable book for dog owners. Calling All Canines…And Their Owners is a lightning fast read, meant to propel the would-be trainer from reading the ‘hows’ to actually ‘doing’ and getting results.

Calling All Canines…And Their Owners is not an all-inclusive volume on dog training; however I don’t think the author intends for it to be. Venza gives enough to get you started and then she wants to you actually go and get started! This is a much more relaxed way to get on the road to consistent dog training than attempting to read and apply a 200+ page hardcover! The book is nicely organized into sections and tackles such subjects as new puppies, jumping, toys, crates, aggression, socialization, and much more. There is also ample room at the end to record your dog’s information, shot records, veterinarian contacts, and additional medical conditions.

Venza’s tone is warm and straightforward throughout her book, and she’s descriptive with all of her methods. This comfortable approach makes learning a new skill less daunting, even for the most apprehensive of would-be trainers. Further, her strategies make use of absolutely no additional tools–there’s no fancy choke collars, toys, clickers, or even treats to purchase before you can get started! Instead, Venza has you off and running immediately. Her justification is simple–the alpha dog in a pack wouldn’t try and coerce its followers with treats, toys, or special training collars. Think like a dog, and you can make your dog act the way you need them to!

Calling All Canines…And Their Owners by Sheri Venza is a fantastic read for those wanting to train their dogs but don’t have a lot of time to sit around and read about it first. Perfect for on-the-go reading, its small size easily fits into bags and can be finished in only a few short sessions. The book is also great for kids who want to be involved in training. The contained methods are easy to adopt, regardless of education level or prior experience with animals. Sit, read, heel!

“The Curious Incident…” a kids’ book through and through

http://norton-scientificcollection.com/collection/2012/09/10/the-curious-incident-a-kids-book-through-and-through/

 A family drama centering on a 15-year old kid with Asperger’s syndrome — think math whiz with tons of behavioral issues. Mark Haddon’s The Curious Incident of the Dog in the Night-time, while amusing was not that remarkable for me. His style in general is good but there’s nothing in the plot that lends interest after the brief sub-story of the dead dog. I want to be disappointed, but it’s a children’s book after all.


 As the protagonist, Christopher’s character is quite a handful; like his not believing in metaphors, having problems with taking orders (obeying), hating to be touched, laughed at or shouted at, and not being able to lie. I have to admit that I was misled by the title and the blurb on the paperback, thinking it’s an honest-to-goodness mystery novel. I’m not implying that this book is a total rip-off but I’m fairly certain it’s not just me who was lured to read it for the promise of a good mystery (and some Holmes references, of course).

Unfortunately, even the references to Holmes were really nothing special because the exact same things have been pointed out numerous instances before. Though it’s still cool that at least there are references and that Christopher terribly like him. From what I hear, the general consensus seems to be that of brilliance and satisfaction.

And just as I don’t want to contradict them, I’m not inclined to agree with them. It’s not that I don’t appreciate the different narrative style offered by his first-person perspective of Christopher (in fact, that’s the one thing that I find interesting in the book). Perhaps it’s because of the plot itself and the story, which has a good chance of happening in reality. Arriving at the last page, I wasn’t really that satisfied.

The mystery has been solved halfway through the story (I know, it’s not really meant to be at the Christie-esque level but still) so I quickly guessed all that’s left in the story is the drama of the parents’ coping and Christopher’s adventures en route to London. Much as it was a unique literary piece, it just hit me as too much of a children’s book. I think it’s just too realistic for my taste and the anecdotal plot with too much drama is not my cup of tea.

Ghost-Written Article at Heart of Pharma Fraud Case

Last month, the biggest health-care fraud settlement in U.S. history was reached, with GlaxoSmithKline (GSK) admitting to federal prosecutors that it essentially paid more than 20 academic researchers to attach their names to a ghost-written article that misrepresented the safety and efficacy of the depression drug Paxil for children. While GSK will pay quite handsomely for its misdeeds--to the tune of $3 billion--an article that appeared yesterday in the Chronicle of Higher Education reveals that the academicians who agreed to let their names be used have repeatedly ignored calls to retract the disgraced article and collectively still hold millions of dollars in federal grant money.

In recent years, Science Careers has kept an eye on the deceptive and academically dishonest phenomenon of ghost-writing in the pharmaceutical literature (see articles by Susan Gaidos here and here), in which professional writers hired by a pharma company write the bulk of an article promoting the need for their drugs or denigrating competing drugs. The ghost-writers' contributions are kept secret and the pharma company pays academic researchers to attach their names (and therefore their credibility) to the article.

The Chronicle article notes that 22 researchers, many of them with university positions, claimed authorship of the Paxil article that appeared in 2001 in the Journal of the American Academy of Child and Adolescent Psychiatry. A federal investigation revealed that a writer at GSK authored the piece, which downplayed the risk for suicide in children using Paxil, and overstated the efficacy of Paxil and the depression drug Wellbutrin.

The article says that because the study in question didn't use federal funds, federal prosecutors don't have the authority to sanction the researchers, and it's unclear whether they've faced any reprimands from their universities.

As for correcting the publication record, the article notes that,

Universities could act on their own to demand that the journal retract the article, said Fiona Godlee, editor in chief of BMJ, another leading medical journal. But, she said, "it is proving hard to get those who should do something to act."

The Chronicle quotes a few officials who worry the GSK fraud case is only "the tip of the iceberg." Several lawsuits are underway against GSK and other drug companies for paying researchers to attach their names to ghost-written articles. Stay tuned to see how this plays out.

David Rakoff Dead: Popular Humorist And Essayist Dies At 47

http://www.huffingtonpost.com/2012/08/10/david-rakoff-dead-dies-aged-47_n_1763783.html?utm_hp_ref=new-york&ir=New%20York

David Rakoff, the popular writer and radio personality, died yesterday of cancer, age 47. He was a frequent contributor to the radio show This American Life, with which he had been involved since its inception, as well as an award-winning essayist.

Last year, he won the highly acclaimedThurber Prize for American Humor for his final essay collection, "Half Empty." His first two books of essays, "Fraud" and "Don't Get Too Comfortable", won the Humor category of the Lambda Literary Awards celebrating excellence in LGBT literature.

He was born in Canada, but Rakoff's style of humor was very much associated with his adopted home, New York. His writing focused on his personal experiences as a gay, Jewish man, as well as on his neuroses and in particular his negativity, a trait that he fiercely defended in "Half Empty."

David Rakoff was friends with the writers Amy and David Sedaris. The latterdescribed Rakoff's work as "truly witty, almost in a lost, old-fashioned way."

His three essay collections were published over 11 years, a relatively low level of output that the writer Edward Champion, who met Rakoff several times, put down to "the high neuroses David brought to the writing process."

He also acted in Off-Broadway plays and movies. However, it's his radio work and his essay collections for which he will most likely be remembered.

David Rakoff was diagnosed with a malignant tumor in 2010. He had already beaten cancer once, aged 22, when he had had a form of lymphatic cancer. While undergoing chemotherapy for the tumor, he went on The Daily Show, where he told Jon Stewart, "The will to keep on going is incredibly strong... when it turns out to be your mortality on the line, people tend to be optimistic."

Update: According to reports, This American Life is preparing a special program dedicated to Rakoff's work, to air next week.

Update 2: The National Post quotes Rakoff's long-time editor Bill Thomas in saying that Rakoff had submitted a finished novel, to be published in the fall. "The book is a novel, in verse, called 'Love, Dishonor, Marry, Die; Cherish, Perish.' I had my doubts about the project when he proposed it, but I was wrong. It is written with humor and sympathy and tenderness, and proves him to be the master of an altogether different art form." A story co-written by Rakoff, about a doctor who only writes in rhyme,was aired last week on This American Life.

Wikinut Norton Collection of Classic and Scientific Literature - ZIMBIO - LIVEJOURNAL

http://nortonscientificcollection-bradkepler.blogspot.co.uk/2012/08/wikinut-norton-collection-of-classic.html Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.

 “While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.

 The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad. Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease. Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque.

The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease. According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop. The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all.

However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.

 “I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies. Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.

Simon Cowell to return to The X Factor to boost ratings

http://uk.omg.yahoo.com/gossip/the-juice/simon-cowell-return-x-factor-boost-ratings-085158209.html


But before you panic that one of the four judges will be losing their seat, Simon won't be coming back in an official judging capacity. An X Factor insider told The Mirror: "

Simon's return is being looked at, certainly. Elements of that have already been filmed and he will definitely appear at the stage where the judges find out which contestants they will be looking after." "We hope there will be more."

 The insider added: "The only difficulty is with Simon being based in the US. The plan is for him to be a significant on-screen part of the show. He's a favourite with viewers." [Related Story: Tom Daley to join The X Factor?] X Factor Executive producer Richard Holloway was a bit more cagey about Mr Cowell's involvement when asked at the Edinburgh TV Festival.

 He said: "Ooh, that would be giving it away, wouldn't it? That's all I'm prepared to say- it's not a hologram." Holloway is adamant, however, that the low ratings are not something to be concerned about. He said: "Our audience for our first show was over double that of the nearest programme."

"We would have liked it to be bigger. However, it's still the number one show on ITV. Viewers are in for a treat over the next three months."
It was reported yesterday that Olympic diver Tom Daley has been drafted in to take part in the live shows later this series.

Tom Daley is reportedly joining the series during the live shows. [Copyright Rex]

<object width="630" height="354"><param name="movie" value="http://d.yimg.com/nl/omg/site/player.swf"></param><param name="wmode" value="opaque"></param><param node="allowFullScreen" value="true"></param><param name="flashVars" value="vid=30373564&lang=en-GB"></param><embed width="630" height="354" src="http://d.yimg.com/nl/omg/site/player.swf" type="application/x-shockwave-flash" flashvars="vid=30373564&autoPlay=false&volume=100&enableFullScreen=1&lang=en-GB"></embed></object>

FOURSQUARE - Norton Scientific Collection Calgary List

http://www.youtube.com/watch?v=gGyIzeoTwRM Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.

Norton Scientific Collection - Zimbio

http://www.zimbio.com/Norton+Scientific+Collection



Bookshelf - Norton Collection of Classic and Scientific Literature
By lucillegosling on August 22, 2012 | From nortoncollection.multiply.com

http://norton-scientificcollection.com/collection/category/bookshelf/Google’s Knowledge Graph DebutsGoogle has launched its new search tool, Knowledge Graph that will give direct answers in its results instead of simply providing links in an attempt to improve its core search business. Now, when you search for a popular place, person … Continue reading →Windows Live Set to RetireMicrosoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications...Read Full Story


Norton Collection of Classic and Scientific Literature
By morrismurphy on August 22, 2012


http://nortonscientificcollection.tumblr.com/ Ivanhoe, the classic novel by Sir Walter Scott, about a valiant knight has been cut and rewritten in an attempt to appeal to modern readers, according to Norton Collection of Classic and Scientific Literature. David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists. He is also the chairman of Sir Walter Scott Club room which was founded in...Read Full Story



Norton Collection of Classic and Scientific Literature
By morrismurphy on August 22, 2012


http://nortoncollectio.livejournal.com/ Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients. “While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head...Read Full Story


Norton Collection of Classic and Scientific Literature-blogger
By mikehancock99 on August 13, 2012


http://nortonscientific-tommcguire.blogspot.com/2012/08/norton-collection-of-classic-and_12.html  NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.Read Full Story


Norton Collection of Classic and Scientific Literature-blogger
By peterchung on August 13, 2012

http://nortonscientific-tommcguire.blogspot.co.uk/2012/08/norton-collection-of-classic-and_12.html  NORTON COLLECTION OF CLASSIC AND SCIENTIFIC LITERATURE One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval and renaissance era through our abundant collection of classic literature.Read Full Story

Bookshelf - Norton Collection of Classic and Scientific Literature

http://norton-scientificcollection.com/collection/category/bookshelf/

Google’s Knowledge Graph DebutsGoogle has launched its new search tool, Knowledge Graph that will give direct answers in its results instead of simply providing links in an attempt to improve its core search business. Now, when you search for a popular place, person … Continue reading →

Windows Live Set to Retire

Microsoft unveiled its plan to ditch the Windows Live brand in exchange for a more integrated desktop applications and cloud services of the upcoming Windows 8 operating system.   Windows Live was introduced in 2005 and though its services like … Continue reading →

Facebook Announces Tweaks on Policy ChangeFacebook has announced another round of updates to previous drafts of its terms of service named Statements of Rights and Responsibilities in an attempt to ease concerns on information sharing and privacy.   “Based on your feedback during the recent … Continue reading →

Norton Scientific Collection :: Care2 Groups (Community Development)

http://www.care2.com/c2c/group/nortonscientificcollection


 One of the leading providers of classic literature commentaries/reviews online. Looking for Edgar Allan Poe? Alexander Dumas? Jane Austen, perhaps? You've come in the right place! Browse right in and find yourself transported back in the medieval

Wikinut: Norton Collection of Classic and Scientific Literature

http://reviews.wikinut.com/Norton-Collection-of-Classic-and-Scientific-Literature/25vew06t/


Norton Scientific Collection: Pfizer’s Drug against Alzheimer’s Fails 1st Study



Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.

“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.

The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.

Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.

Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.

According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.

The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.

“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies.

Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.

Norton Scientific by Brad Kepler - PPT Presentation

http://www.powershow.com/view/3a9a96-YTY5N/Norton_Scientific_by_Brad_Kepler_flash_ppt_presentation

     Download

More Sharing ServicesShare

About This Presentation

Title:Norton Scientific by Brad Kepler

Description:

Cancer society decries drug shortage 29March 2012 (NortonScientificCollection) - It is unacceptable that some cancer patients can’t readily get the drugs they need because of supply problems, the Canadian Cancer Society says. The society is hearing from worried patients and doctors across the country, said Dan Demers, the group's director of public issues. – PowerPoint PPT presentation

Number of Views:19

Ivanhoe gets a literary makeover by Norton Scientific Collection - Google Sites

https://sites.google.com/site/nortonscientificcollection/home/collection

Ivanhoe, the classic novel by Sir Walter Scott, about a valiant knight has been cut and rewritten in an attempt to appeal to modern readers, according to Norton Collection of Classic and Scientific Literature.



David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists.



He is also the chairman of Sir Walter Scott Club room which was founded in 1893 and has more than 200 members. Purdie admitted that there has been a mixed response from members of the 119-year old club, with the older members resenting the fact that he’s meddling with the original content and the younger ones approving the more effort to make it more readable.



Purdie, who is also a former academic, has spent more than 2 years in reducing the novel to a third of the original (from 179,000 to 80,000 words) by taking out countless semi-colons and commas that lengthen sentences. Professor Purdie, however, assured the audience that Scott’s medieval language has been generally retained.

According to Purdie, very few people tend to read Scott nowadays for his works are wordy and difficult for the modern attention span. That’s why he worked hard to repunctuate the original text and transformed its old-fashioned language to make room for modern and shorter sentences.



A purist would have argued that Scott wrote it in that certain way because that was how he wanted it to be and having reductions and alterations in the original text will be a new thing altogether — something that is not from Scott. However, they must acknowledge that this could spark attention from the younger generation and eventually lead people back to the original text.



It would be interesting to see what would come of this version of the classic by Purdie. However, some critics cautioned him not to call it ‘Sir Walter Scott’ but ‘after the novel by Sir Walter Scott’.



Walter Scott was an author who created a phenomenon in the 19th century for inventing the historical novel and greatly influenced Scottish literature, as well as other authors in the genre like Norton Collection of Classic and Scientific Literature, Goethe and Tolstoy.



Despite the long-winded prologue and descriptions that come with the original story, Ivanhoe has many fans which include the famous Vietnamese, Ho Chi Minh and former UK Prime Minister Tony Blair.

Palladium More Effective Against Carcinogen

http://norton-scientificcollection.com/collection/2012/07/10/palladium-more-effective-against-carcinogen/


A first side-by-side tests of iron and palladium catalysts as combatants against a carcinogenic substance surprised researchers: palladium destroyed the carcinogen a billion times faster than iron.
Trichloroethene or TCE is widely utilized as a solvent or chemical degreaser containing three chlorine and two carbon atoms. Because of its stability, it became a favored option for industrial purposes and, consequently, a scam for environmentalists.
Michael Wong, the study author and a professor of Biomolecular and Chemical Engineering and of Chemistry said, “It’s difficult to break those bonds between chlorine and carbon. Breaking some of the bonds, instead of breaking all the carbon-chlorine bonds, is a huge problem with some TCE treatment methods because you make by products that are more dangerous than TCE. The popular approaches are, thus, those that do not break these bonds. Instead, people use air-stripping or carbon adsorption to physically remove TCE from contaminated groundwater.”
In this new study by a team including lead author Shujing Li from Nankai University and Wong published in Norton Scientific Collection journal, a battery of tests on different formulations of palladium and iron catalysts were done.
Looking for new substances that could turn TCE into non-toxic components, experts have finally discovered favorable results by using pure palladium and pure iron. Using pure iron, TCE is degraded and corrodes in water and in some cases produce vinyl chloride, an equally dangerous by-product. Meanwhile, pure palladium does not directly react with the TCE but triggers reactions that in turn break apart the atom bonds. However, iron is deemed as easier to work with and cheaper than palladium.
“These methods are easy to implement but are expensive in the long run. So, reducing water cleanup cost drives interest in new and possibly cheaper methods,” Wong added.
Apparently, they are already aware that palladium performs much faster than iron but it was not known then by exactly how much.
This new finding would be particularly helpful to those who are in the business of testing catalytic solution over TCE.

Pfizer’s Drug Against Alzheimer’s Fails 1st Study

http://norton-scientificcollection.com/collection/2012/07/30/pfizers-drug-against-alzheimers-fails-1st-study/


Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s disease has failed to show signs of effectiveness in one of the four late-stage tests in patients.

“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained following the availability of additional data,” said Pfizer’s head of primary care medicines development.

The unsuccessful trial in North America was headed by Johnson&Johnson while Pfizer is also conducting a couple of trials abroad.

Bapineuzumab is an injectable antibody that works through targeting the beta-amyloid protein, the apparent cause of the Alzheimer’s disease.

Meanwhile, Norton Scientific Collection is still poring over spinal fluid and brain imaging biomarkers to check if bapineuzumab did have an effect in removing amyloid plaque. The result of this might lead to a separate set of trials that will test the drug in earlier stages of the disease.

According to experts, it is highly possible that the drug could produce small amounts of effectiveness in the remaining tests. Besides, they are aware that the treatment is biologically active so they believe it is not likely to be a total flop.

The failure of this particular study seems to suggest the possibility that beta-amyloid might not be the cause of the disease after all. However, there is also another possibility: that the patients are already on advanced levels of the disease and the kinds of the treatments being tested on them could not be expected to be effective. Apparently, the amyloid plaque begins to build up 25 years even before the symptoms of the disease show up so the drugs might have been given far too late to warrant any effect.

“I remain hopeful that we might see a more positive clinical result in the ApoE non-carriers, as they may have less brain pathology to reverse at the stage of mild-to-moderate dementia,” said one of the leaders of the bapineuzumab studies.

Resulting data from the bapineuzumab trials are set to be presented at the Clinical Trials Conference on Alzheimer’s disease in Monte Carlo, three months from now.

Norton Scientific Collection: China’s VP Visits White House

http://knol.google.com/k/stanley-norton/norton-scientific-collection-ivanhoe/6afgrsm9l8mo/1#

US President Barack Obama has sat down in a meeting with the next leader of China to discuss matters regarding same trade rules, human rights policies, military intentions and perhaps, to also gauge what the next administration will be like.

China’s vice president, Xi Jinping, was welcomed in the White House as part of a carefully planned tour that includes a Pentagon visit complete with a 19-gun salute.

The 58-year old Xi is in line to lead the ruling Communist Party this year before he assumes presidency of China in March 2013.

Obama was apparently frank with Xi Jinping, pushing him on sensitive issues such as human rights and economy as well as those concerning Syria and Iran.

The Chinese leader did not directly address Obama’s veiled criticisms on their meeting in front of the media but said that he is looking forward to building a ‘cooperative partnership based on mutual respect’.

Xi said that his trip is not only for political purposes but also to establish a deeper friendship with the American.

US announced that would like to work alongside China in ensuring that everyone is following the same rules on global economic system, with special attention on balanced trade flow.

US seems to be disappointed in China’s vetoing, along with Russia, of UN resolution against Syria’s leader Bashar al-Assad, emphasizing a sharp policy difference between the two.

The Congress has openly expressed its worry that Chinese practices like keeping their currency’s value ‘artificially’ low than the dollar puts US companies at a disadvantage.

The two leaders are in agreement that they should work in restoring trust between their countries. This is in connection to their strained military ties — with China building up its force and US reasserting itself in Asia-Pacific.

Obama has said US welcomes China’s ‘peaceful rise’ but also cautioned that the ‘friction’ will stay present in a growing military and economic rivalry between the 2 nations.

Xi has cautioned US officials, in order to avoid further damage and disturbance in their relations, not to meddle with how they respond to delicate issues such as those concerning Tibet and Taiwan.

Current Chinese President Hu Jintao has made similar statements in his visit to Washington last year, recognizing that China does not necessarily share the West’s human rights concepts and believing that China’s national characteristics should be taken into consideration.

Multiply - Norton Scientific Collection: Hubpages: Norton Collection of Classic and Scientific Literature - Yousaytoo

http://www.yousaytoo.com/multiply-norton-scientific-collection-hubpages-norton-collection-of-cla/1887151

Simultaneous events were held worldwide in celebration of the 200th birthday of Charles Dickens — the man who wrote A Christmas Carol, Oliver Twist, A Tale of Two Cities,Norton Collection of Classic and Scientific Literature, David Copperfield and Great Expectations. 
Dickens surely takes his time and mostly does not go directly to the point. In fact, during his time, he publishes his works in installments (which is cheaper than whole novels and easier to market). Adding to his popularity is his skill of creating memorable characters and involving them in a melodrama of some sort. 
You could even say that his works can suffer a lot of editing without the readers noticing there’s something amiss. But his long-windedness is one of his selling point. Too bad, because nowadays many are after brevity. 
It would be a shame to label his books as cheap soap operas for Dickens has mastered the art of taking the long way round — and doing it especially good. 
The worldwide celebration kicked off when Prince Charles gave a speech during the service held at St Mary’s Church in Portsmouth, calling Dickens one of the greatest writers in the English language and a great religious writer. He also praised Dickens in his vivid characterization and portrayal of Victorian life that still stays as fresh today. Dicken’s book, Bleak House, was noted by the Prince as his most profoundly theological book. 
Ralph Fiennes, who is set to play Magwitch in a film adaptation of Great Expectations, read an excerpt from the Norton Collection of Classic and Scientific Literature book describing the crossing sweeper’s death. 
Meanwhile, an excerpt from ‘The Life of Our Lord’ was read by one of his descendants. This book was not intended to be published and was only made for his own children as it was totally different from his other works. 
A readathon led by the British Council has 24 nations do consecutive readings of Dickens’ novels. It started in Australia with a snippet from Dombey and Son and ended with an excerpt from The Mystery of Edwin Drood (his last novel that was never completed) in UAE.

Norton Scientiific Collection | Gather

http://nortonsccollect.gather.com/

Norton Scientific Collection: 200 years of Charles Dickens | Norton Collection of Classic and Scientific Literature by John Marx

Simultaneous events were held worldwide in celebration of the 200th birthday of Charles Dickens — the man who wrote A Christmas Carol, Oliver Twist, A Tale of Two Cities, Norton Collection of Classic and Scientific Literature, David Copperfield and Great Expectations.

Dickens surely takes his time and mostly does not go directly to the point. In fact, during his time, he publishes his works in installments (which is cheaper than whole novels and easier to market).

Norton Collection of Classic and Scientific Literature by Toni Heading

February 07, 2012 06:08 AM EST

http://norton-scientificcollection.com/collection/

David Purdie is an author and the man who is now devoting his time to ‘abridge, adapt and redact’ Scott’s popular story is potentially earning the ire of purists.

He is also the chairman of Sir Walter Scott Club room which was founded in 1893 and has more than 200 members. Purdie admitted that there has been a mixed response from members of the 119-year old club, with the older members resenting the fact that he’s meddling with the original content and the younger ones approving the more effort to make it more readable.

Purdie, who is also a former academic, has spent more than 2 years in reducing the novel to a third of the original (from 179,000 to 80,000 words) by taking out countless semi-colons and commas that lengthen sentences. Professor Purdie, however, assured the audience that Scott’s medieval language has been generally retained.

Norton Scientific Collection: 200 years of Charles Dickens

http://norton-scientificcollection.com/collection/2012/02/09/norton-scientific-collection-200-years-of-charles-dickens/comment-page-1/


Simultaneous events were held worldwide in celebration of the 200th birthday of Charles Dickens — the man who wrote A Christmas Carol, Oliver Twist, A Tale of Two Cities, Norton Collection of Classic and Scientific Literature, David Copperfield and Great Expectations.



Dickens surely takes his time and mostly does not go directly to the point. In fact, during his time, he publishes his works in installments (which is cheaper than whole novels and easier to market). Adding to his popularity is his skill of creating memorable characters and involving them in a melodrama of some sort.



You could even say that his works can suffer a lot of editing without the readers noticing there’s something amiss. But his long-windedness is one of his selling point. Too bad, because nowadays many are after brevity.



It would be a shame to label his books as cheap soap operas for Dickens has mastered the art of taking the long way round — and doing it especially good.



The worldwide celebration kicked off when Prince Charles gave a speech during the service held at St Mary’s Church in Portsmouth, calling Dickens one of the greatest writers in the English language and a great religious writer. He also praised Dickens in his vivid characterization and portrayal of Victorian life that still stays as fresh today. Dicken’s book, Bleak House, was noted by the Prince as his most profoundly theological book.



Ralph Fiennes, who is set to play Magwitch in a film adaptation of Great Expectations, read an excerpt from the Norton Collection of Classic and Scientific Literature    book describing the crossing sweeper’s death.



Meanwhile, an excerpt from ‘The Life of Our Lord’ was read by one of his descendants. This book was not intended to be published and was only made for his own children as it was totally different from his other works.



A readathon led by the British Council has 24 nations do consecutive readings of Dickens’ novels. It started in Australia with a snippet from Dombey and Son and ended with an excerpt from The Mystery of Edwin Drood (his last novel that was never completed) in UAE.

Norton Collection of Classic and Scientific Literature

http://norton-scientificcollection.yolasite.com/

The Blog is provided by Norton Collection of Classic and Scientific Literature in good faith. However,Norton Scientific does not make any representations or warranties of any kind, implied or express, in relation to all or any part of the Blog or the Content or any websites to which the Blog is linked, and all warranties and representations are hereby excluded to the extent permitted by law.

There is no guarantee that the Blog will be free of infection by viruses or anything else which may be digitally harmful or destructive.

Norton Collection of Classic and Scientific Literature hereby waives all liability (howsoever arising) in connection with any loss and/or damage, arising out of or in connection with any use of, or inability to use, all or any part of the Content, the Blog and/or any website to which the Blog is linked, or any action taken (or refrained from being taken) as a result of using any of these.